The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy

► Cancers are divided into very small subgroups carrying a rare molecular alteration. ► Most of the new drugs are targeting these infrequent events. ► Trials are testing the use of high throughput technologies in personalized medicine. ► Circulating tumor cells and virtual cell program could optimize genomic testing. ► Future clinical research will focus in target identification at a patients level.